Beijing Scitop Bio-tech Co (300858) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 reached ¥104.04 million, up 28.98% year-over-year; YTD revenue was ¥267.39 million, up 22.25% year-over-year.

• Net profit attributable to shareholders for Q3 was ¥35.03 million, up 26.56% year-over-year; YTD net profit was ¥76.23 million, up 7.08% year-over-year.

• Adjusted net profit (excluding non-recurring items) for Q3 was ¥31.95 million, up 36.18% year-over-year; YTD adjusted net profit was ¥67.08 million, up 9.79% year-over-year.

Financial highlights

• Basic and diluted EPS for Q3 were ¥0.13, up 18.18% year-over-year; YTD EPS was ¥0.29, up 7.41% year-over-year.

• Operating cash flow for Q3 was ¥72.60 million, down 32.57% year-over-year.

• Total assets at Q3-end were ¥1.94 billion, up 1.32% from year-end 2024.

• Shareholders’ equity at Q3-end was ¥1.83 billion, up 2.05% from year-end 2024.

Outlook and guidance

• The company completed its 2024 equity distribution plan in July 2025 and adjusted the restricted stock incentive grant price from ¥12.85 to ¥12.70 per share in August 2025.